Toggle light / dark theme

In first-of-their-kind observations in the human brain, an international team of researchers has revealed two well-known neurochemicals–dopamine and serotonin–are at work at sub-second speeds to shape how people perceive the world and take action based on their perception.

Furthermore, the neurochemicals appear to integrate people’s perceptions of the world with their actions, indicating dopamine and serotonin have far more expansive roles in the human nervous system than previously known.

Known as neuromodulators, dopamine and serotonin have traditionally been linked to reward processing–how good or how bad people perceive an outcome to be after taking an action.

The study online today in the journal *Neuron* opens the door to a deeper understanding of an expanded role for these systems and their roles in human health.

“An enormous number of people throughout the world are taking pharmaceutical compounds to perturb the dopamine and serotonin transmitter systems to change their behavior and mental health,” said P. Read Montague, senior author of the study and a professor and director of the Center for Human Neuroscience Research and the Human Neuroimaging Laboratory at the Fralin Biomedical Research Institute at Virginia Tech Carilion. “For the first time, moment-to-moment activity in these systems has been measured and determined to be involved in perception and cognitive capacities. These neurotransmitters are simultaneously acting and integrating activity across vastly different time and space scales than anyone expected.”

“These neuromodulators play a much broader role in supporting human behavior and thought, and in particular they are involved in how we process the outside world,” Bang said. “For example, if you move through a room and the lights are off, you move differently because you’re uncertain about where objects are. Our work suggests these neuromodulators–serotonin in particular– are playing a role in signaling how uncertain we are about the outside environment.”

The CRISPR/Cas9 gene-editing tool is one of the most promising approaches to advancing treatments of genetic diseases—including cancer—an area of research where progress is constantly being made. Now, the Molecular Cytogenetics Unit led by Sandra Rodríguez-Perales at the Spanish National Cancer Research Centre (CNIO) has taken a step forward by effectively applying this technology to eliminate so-called fusion genes, which in the future could open the door to the development of cancer therapies that specifically destroy tumors without affecting healthy cells. The paper is published in Nature Communications.

Fusion genes are the abnormal result of an incorrect joining of DNA fragments that come from two different genes, an event that occurs by accident during the process of cell division. If the cell cannot benefit from this error, it will die and the will be eliminated. But when the error results in a reproductive or survival advantage, the carrier cell will multiply and the genes and the proteins they encode thus become an event triggering tumor formation. “Many and the fusion genes they produce are at the origin of childhood sarcomas and leukaemias,” explains Sandra Rodríguez-Perales, lead co-author of the study now published by the CNIO. Fusion genes are also found in among others prostate, breast, lung and brain tumors: in total, in up to 20% of all cancers.

Because they are only present in tumor cells, fusion genes attract a great deal of interest among the scientific community because they are highly specific therapeutic targets, and attacking them only affects the tumor and has no effect on .

In August, the US Air Force Research Laboratory 711th Human Performance Wing launched its iNeuraLS project, an effort to speed up pilot training through brain stimulation.


Some will feel a slight tingling sensation. Others will feel nothing at all.

The electrode placed inside the ear canal isn’t designed to shock. Rather, the US Air Force Research Laboratory (ARFL) believes the earbud-like device, when placed next to the brain’s vagas nerve, will have more of an intellectually stimulating effect. It ought to create moments of super learning, controllable periods of focus that allow pilots to soak up their flight training faster than humanly possible.

Circa 2013


“When the induced field is above a certain threshold, and is directed in an appropriate orientation relative to the brain’s neuronal pathways, localized axonal depolarizations are produced, thus activating the neurons in the relevant brain structure.”

First the machine is calibrated by placing it over a part of the brain that causes the subject’s hand to move. Then the coils are aimed at the brain region under treatment. The treatment lasts about 15 to 30 minutes, repeated over several weeks, and is noninvasive–all the person feels is a slight buzzing, and there are no side effects. This makes it a more palatable relative of other treatments that also target the brain directly, such as electroconvulsive therapy (formerly electroshock), or surgically implanted electrodes.

Summary: Boosting levels of the DUSP4 protein could be a novel way of preventing and treating epilepsy.

Source: University of Illinois

Epileptic seizures often originate in small, localized areas of the brain where neurons abnormally fire in unison. These electrical impulses disrupt proper brain functioning and cause seizures. But what makes regions where seizures start different from parts of the brain where electrical impulses remain normal? More importantly, what prevents these epileptic centers from growing?

Researchers have made a breakthrough genetic discovery into the cause of a spectrum of severe neurological conditions.

A research study, led by the Murdoch Children’s Research Institute (MCRI) and gracing the cover of and published in the October edition of Human Mutation, found two new in the KIF1A gene cause rare nerve disorders.

MCRI researcher Dr. Simranpreet Kaur said mutations in the KIF1A gene caused ‘traffic jams’ in , called neurons, triggering a devastating range of progressive brain disorders. KIF1A-Associated Neurological Disorders (KAND) affects about 300 children worldwide.